$60.1 Million

Exagen Inc.

Follow-on Offering

Lead Left Bookrunner, March 2021

Exagen Inc. (“Exagen” or the “Company”) is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The Company has developed and is commercializing a portfolio of innovative testing products under the AVISE brand, several of which are based on their proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus.

More Like This

Apr 2021
$165.6 Million

Follow-on Offering

Lead Left Bookrunner

View Details
Mar 2021
$30 Million
Verrica Pharmaceuticsls

Follow-on Offering

Bookrunner

View Details
Mar 2021
$56 Million

Follow-on Offering

Lead Left Bookrunner

View Details